Extended-field versus Whole-pelvis Concurrent Chemoradiation for Locally-advanced Cervical Cancer Patients with Radiologic Negative Para-aortic Lymph Node: A Systematic Review

Authors

  • Sangkittipaiboon S, Sukhaboon J

Keywords:

Cervical cancer, Chemoradiation, Lymph node, Extended-field, Survival, Toxicity

Downloads

Download data is not yet available.

References

International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 [cited 2017 Apr 8]. Available from: http://globocan.iarc.fr

Imsamran W, Pattatang A, Supattagorn P, Chiawiriyabunya I, Namthaisong K, Wongsena M, et al. Cancer in Thailand Vol. IX, 2013-2015. Bangkok: National Cancer Institute; 2015.

Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154-61.

Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137-43.

Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606-13.

Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-53.

Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17: 1339-1348.

Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, KolesnikovGauthier H, et al. Nodal-staging surgery for locally advanced cervical cancer in the era of PET. Lancet Oncol 2012; 13: e212-20.

Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22: 872-80.

Liang JA, Chen SW, Chang WC, Hung YC, Yeh LS, Yang SN, et al. Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results. Clin Oncol 2008; 20: 683-90.

Berman ML, Keys H, Creasman W, DiSaia P, Bundy B, Blessing J. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol 1984; 19: 8-16.

Goff BA, Muntz HG, Paley PJ, Tamimi HK, Koh WJ, Greer BE. Impact of surgical staging in women with locally advanced cervical cancer. Gynecol Oncol 1999; 74: 436-42.

Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994; 29: 9-16.

Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol 2013; 3: 34.

Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Long-term follow-up of RTOG 92-10: cervical cancer with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2001; 51: 982-7.

Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1998; 42: 1015-23.

Small W Jr, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 2007; 68: 1081-7.

Walker JL, Morrison A, DiSilvestro P, von Gruenigen VE. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the paraaortic lymph nodes: a Gynecologic Oncology Group study. Gynecol Oncol 2009; 112: 78-84.

Sood BM, Gorla GR, Garg M, Anderson PS, Fields AL, Runowicz CD, et al. Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy. Cancer 2003; 97: 1781-8.

Kim YS, Kim JH, Ahn SD, Lee SW, Shin SS, Nam JH, et al. High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2009; 74: 1522-8.

Chung YL, Jian JJ, Cheng SH, Hsieh CI, Tan TD, Chang HJ, et al. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatinbased chemotherapy for locally advanced cervical cancer: a phase I/II study. Gynecol Oncol 2005; 97: 126-35.

Jensen LG, Hasselle MD, Rose BS, Nath SK, Hasan Y, Scanderbeg DJ, et al. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin. Int J Gynecol Cancer 2013; 23: 119-25.

Zhang G, Fu C, Zhang Y, Wang J, Qiao N, Yang Q, et al. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution. Int J Gynecol Cancer 2012; 22: 1220-5.

Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1085-91.

Kazumoto T, Kato S, Yokota H, Hasumi Y, Kino N, Horie K, et al.Is a low dose of concomitant chemotherapy with extendedfield radiotherapy acceptable as an efficient treatment for cervical cancer patients with metastases to the para-aortic lymph nodes? Int J Gynecol Cancer 2011; 21: 1465-71.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ 2009; 339: b2535.

Centre for reviews and dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. York: University of York; 2006.

Higgins JPT, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration; 2011. [Accessed February 22, 2016]. Available from: www. cochrane-handbook.org.

Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015; 8: 2-10.

Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 2014; 14: 45.

Asiri MA, Tunio MA, Mohamed R, Bayoumi Y, Alhadab A, Saleh RM, et al. Is extended-field concurrent chemoradiation an option for radiologic negative paraaortic lymph node, locally advanced cervical cancer? Cancer Manag Res 2014; 6: 339-48.

Yap ML, Cuartero J, Yan J, Pintilie M, Fyles A, Levin W, et al. The role of elective para-aortic lymph node irradiation in patients with locally advanced cervical cancer. Clin Oncol 2014; 26: 797-803.

Liang JA, Chen SW, Hung YC, Yeh LS, Chang WC, Lin WC, et al.Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes. Int J Gynecol Cancer 2014; 24: 901-7.

Tsai CS, Chang TC, Lai CH, Tsai CC, Ng KK, Hsueh S, et al. Preliminary report of using FDG-PET to detect extrapelvic lesions in cervical patients with enlarged pelvic lymph nodes on MRI/CT. Int J Radiat Oncol Biol Phys 2004; 58: 1506-12.

Stoeckli SJ, Mosna-Firlejczyk K, Goerres GW. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography. Eur J Nucl Med Mol Imaging 2003; 30: 411-6.

Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. Int J Radiat Oncol Biol Phys 2005; 63: 492-9.

Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010; 28: 2108-13.

Published

01-08-2018

How to Cite

1.
สมภพ แสงกิตติไพบูลย์ พ.บ., จิรศักดิ์ สุขาบูรณ์ พ.บ. Extended-field versus Whole-pelvis Concurrent Chemoradiation for Locally-advanced Cervical Cancer Patients with Radiologic Negative Para-aortic Lymph Node: A Systematic Review. j dept med ser [Internet]. 2018 Aug. 1 [cited 2022 Aug. 13];43(4):154-61. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/248018

Issue

Section

Original Article